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Background: Sarcoidosis is generally treated with corticosteroids that are not always an
effective therapy.
Objectives: To assess if treatment with antifungal drugs would improve the clinical status
of patients with sarcoidosis.
Methods: Patients (n ¼ 18) with sarcoidosis grades II and III according to established
criteria and without clinical and immunological signs of fungal infection, were treated with
antifungal medication together with corticosteroids for 3–6 months. Pulmonary X-ray
infiltration, lung function, and severity of symptoms were registered before and after the
treatment and at follow up 9–58 months later.
Results: The treatment resulted in statistically significant decreases in the degree of
pulmonary infiltration with an average decrease in the group from 2.0 to 1.0. There were
also significant increases in diffusion capacity and decreases in the severity of symptoms.
Conclusion: It is suggested that treatment with antifungal drugs may be useful, at least in
certain cases of sarcoidosis.
& 2006 Elsevier Ltd. All rights reserved.Introduction
In spite of extensive research efforts over many years, the
aetiology of sarcoidosis remains an enigma.1 Recent reviews
have demonstrated that mycobacteria as well as other
micro-organisms remain primary suspects although noElsevier Ltd. All rights reserved.
22 2342.
clj.si (M. Tercelj).convincing evidence is available.2,3 A few clinical and
epidemiological studies support a role for mould exposure.
In a case control study using questionnaires, cases of
sarcoidosis were found to have a more frequent exposure
to fungi at the workplace and to moisture problems at home
than controls, but the response rate was very low both
among cases and controls.4 Occupational risk factors were
studied among 273 cases of sarcoidosis and 618 siblings
without the disease.5 Specific exposures that were asso-
ciated with the disease and imply possible fungal exposures
ARTICLE IN PRESS
Antifungal treatment in sarcoidosis 775were vegetable dusts, and indoor exposure to high humidity,
water damage or musty odours. In a case-control study on
706 newly recruited cases of sarcoidosis and equal numbers
of age-, race-, and gender-matched controls, there were
positive associations between sarcoidosis and agricultural
employment, and work environments with mould/mildew
exposure.6
One of the authors (MT) made a clinical observation that
the treatment of fungal foci (candida vaginitis and sinusitis)
present in three patients with sarcoidosis brought about an
unexpected improvement in lung X-ray findings. To further
assess this finding, a pilot intervention trial was undertaken
with the hypothesis that treatment of cases with sarcoidosis
with antifungal medication would improve their clinical
condition.Material and methods
Patients
The clinical material comprised patients with sarcoidosis
diagnosed at the University hospital in Ljubljana. The
patients for the study (n ¼ 18) were selected from those
with a stage II or III disease with poor or no clinical
regression after at least 6 months of treatment with
corticosteroids (prednisolone 12 or 16mg every second
day) or patients with a relapse after discontinuation of
treatment. Inclusion criteria were X-ray-diagnosed bilateral
parenchymal infiltrates corresponding to stages II and III
according to the ATS classification.7 Lung biopsies were
taken from all patients. The presence of non-caseating
granulomas was verified histologically and all biopsies were
stained and about half of them were cultured to exclude the
presence of fungal infection. No biopsies were taken after
the corticosteroid treatment prior to antifungal treatment.Examinations
The X-rays comprised standard front views of the chest in
erect position, at 150 kv and 200 cm focus–film distance,
automatic exposure in deep inspiration (Ferrania Chest GbB
7700 501 films with standard automatic developing). There
was no evidence of aspergillomas on X-ray or CT scanning
before antifungal treatment (cavities, pleural thickening or
other findings indicative of aspergillosis).
The X-rays were scored for extent of infiltration
(0 ¼ normal, 1 ¼ ca 25% of lung field involved, 2 ¼ up to
50%, 3 ¼ up to 75%, and 4 ¼ virtually the whole lung field
involved) by two experienced radiologist and four residents
not knowing the patient’s identity, diagnosis or the date of
X-ray examination. There was a disagreement between the
groups for two X-rays and these were assigned according to
the less favourable score.
Measurements were made of forced expiratory volume in
1 s (FEV1), vital capacity (VC) and lung diffusion (DLCO,
n ¼ 17) according to the ATS criteria and expressed as % of
expected. Serum angiotensin converting enzyme (SACE) was
measured in serum using standardised methods. Immunolo-
gical examinations were made before and after antifungal
treatment and comprised fungal IgG, IgM, and IgA antibodiesin serum but antibody titre was not used to judge the
efficiency of the treatment.
Information on the presence of symptoms was obtained in
structured interviews before and after the treatment, using
a numerical scale for severity of cough (1 ¼ mild,
2 ¼ moderate, 3 ¼ severe, every day, 4 ¼ severe, day and
night), dyspnoea (1 ¼ on heavy exercise, 2 ¼ on moderate
exercise, 3 ¼ on minimal exercise, 4 ¼ at rest), chest pains
(1 ¼ little pain, 2 ¼ moderate pain, 3 ¼ severe pain,
4 ¼ very severe pain), malaise (yes/no), and increase in
body temperature (437 1C).
Treatments
The patients were treated with antifungal drugs—Itrakona-
sol, Fluconasol, and Ketonazol (all at 200mg/day) together
with corticosteroids in the usual dose. At 3–6 months, after
initiation of antifungal treatment, the dose was decreased
to 4–6mg. The choice between the drugs was made based on
the presence of antibodies to Aspergillus or Candida. If no
clear differences in titre were present, Flukonasol was
chosen. Liver function was tested before and every second
week throughout fungal treatment. No indications for
discontinuation of treatment were found. One patient
discontinued antifungal treatment after 2 months by her
own and was excluded from the material. A summary of the
patient characteristics is presented in Table 1.
The duration of corticosteroid treatment before the
intervention (n ¼ 11) was 26 months (range 14–48 months).
Seven of the patients had been without corticosteroid
treatment for 2–36 months when they had a relapse in their
disease. The antibody levels were below those generally
considered to reflect an ongoing fungal infection.
Treatment of data
For each individual, the difference before and after
treatment was calculated for X-ray readings, lung function
and severity of symptoms. The presence of positive values
(deterioration) or negative values (improvement) before
and after treatment were tested for significance using
Wilcoxon’s signed rank test, with Po0:05 as the critical
value for statistical significance.
Follow-up
A follow-up comprising X-ray was made 9–58 months after
cessation of antifungal treatment.
Results
The results from the X-ray scores at the time of diagnosis of
sarcoidosis, after corticosteroid treatment and after anti-
fungal+corticosteroid treatment are seen in Table 2.
There were no significant differences in scores between
the time at diagnosis and after corticosteroid treatment.
The difference before and after antifungal+corticosteroid
treatment was significant (Po0:001). One patient improved
2.5 points, two 2 points, three 1.5 points, three 1 point,
seven 0.5 point and two were unchanged. Sixteen persons
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Table 1 Background characteristics of patients.
Age Gender Disease stage Corticosteroid treatment G titres units/ml Drug
A B Aspergillus Candida
42 F 2 32 — 0 o 30 K
34 F 2 27 — 70 ND I
37 F 2 14 — o30 o30 I
43 M 2–3 17 — o30 o30 F
50 M 2 — 10 o30 0 I
41 M 2–3 36 — 18? 61 I
44 F 2 18 — 39 42 F
48 F 2–3 36 — 74 o30 F
41 M 2 48 — 175 9 I
42 F 2–3 — 5 25 o30 I
44 M 2 — 9 o30 o30 F
57 M 2 24 — 77 172 I
34 M 2–3 — 2 o30 o30 F
40 F 2 — 17 90 133 F
51 F 2 19 — 49 60 F
59 F 2 — 36 o30 o30 I
67 F 2–3 — 10 35 40 F
31 M 2–3 17 — o30 o30 I
Corticosteroid treatment: A ¼ months treatment before antifungal treatment was initiated, B ¼ months without treatment before
relapse of disease and start of antifungal treatment. Treatment with Flukonasol (F), Itrakonasol (I) or ketonazol (K).
Table 2 X-ray scores of pulmonary infiltration among
patients at diagnosis of sarcoidosis (A), after corticoster-
oid treatment (B), after antifungal +corticosteroid treat-
ment (C) and at follow-up (D).
Subject A B C D
1 2.5 2.5 1.0 0
2 2.0 3.5 1.0 0
3 2.5 2.5 1.0 0
4 3.0 2.0 1.0 1
5 1.0 0.5 0.5 0
6 2.0 3.0 1.0 1.5
7 2.0 1.5 1.0 1
8 2.0 1.5 1.0 1
9 3.0 2.0 1.5 0
10 1.5 1.0 0.5 0.5
11 2.5 2.0 1.5 0
12 1.0 2.0 2.0 1
13 1.0 1.5 0.0 0
14 2.0 2.0 1.5 0
15 3.0 2.0 1.0 2
16 3.0 2.0 0.0 1
17 1.5 2.0 1.0 2
18 3.0 2.5 2.0 0.5
Mean 2.1 2.0 1.0 0.6
M. Tercelj et al.776had scores in excess of 1 before treatment as compared to
five after treatment.
For DLCO, 15 out of 17 subjects improved. The mean
value in the group before treatment was 86.1, SD 9.5% ascompared to 92.1, 7.3% after treatment (P ¼ 0:022). There
were no significant differences in FEV1 or VC before and
after the treatment (data not shown). There were no
significant differences in SACE values before and after
treatment.
Regarding symptoms, the severity of cough was lower
after antifungal treatment as compared to before among 12
persons (P ¼ 0:003). Dyspnoea was lower among 14
(P ¼ 0:001) and chest pains were lower among 13
(P ¼ 0:001). Seven persons had persistent fever (4371)
before the treatment compared to none afterwards.
At the follow-up, 15 patients had been without corticos-
teroid treatment for 6–55 (average 16) months. Nine
patients had a lower score than at cessation of antifungal
treatment (Table 2), four were unchanged and four had
increased scores. Figure 1 presents the average X-ray score
at different times during the investigation.Discussion
The results from the study support the initial observation
that treatment with antifungal medication improved the
clinical and subjective signs of sarcoidosis among the
majority of patients studied.
There are, however, some methodological aspects that
need to be considered.
The X-ray evaluation involved a subjective scoring of the
extent of infiltration in a double-blind manner. There are
other alternatives for grading but this was considered a
robust measure and, as the results are expressed as a
comparison between two readings for each patient, the
result should be reliable.
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Figure 1 Average X-ray scores in relation to treatments.
Antifungal treatment in sarcoidosis 777The patients were by purpose selected among those who
had a long-term history of the disease or who relapsed after
discontinuation with the traditional corticosteroid treat-
ment. It cannot be excluded, however, that some patients
could have hade a spontaneous recovery which is a well-
known phenomenon in sarcoidosis. On the other hand,
experience demonstrates that spontaneous recovery is rare
for patients with chronic disease of long duration. It could
have occurred in some of the patients but cannot account
for the overall improvement that was found after the
antifungal treatment.
The antifungal medication was not administered in a
double-blind design. This will be required in further studies
to verify the findings from this preliminary study. It is
unlikely, however, that the general improvements in lung
X-ray scores were a placebo effect.
There are several possible explanations for the improve-
ments described. It is possible that the antifungal drugs as
such had some unknown effect on the immune system,
causing a regression of pulmonary infiltrates and subjective
symptoms. No such effects have, however, been described
for the antifungal agents used. It is also possible that the
antifungal drugs could have improved the efficiency of the
combined treatment with corticosteroids. On the other
hand, the treatment with corticosteroids before the anti-
fungal treatment comprised treatment with optimal doses
without clinically significant results in 11 of the patients in
the study.
A challenging possibility is that fungi present in the
patients could have been of importance. Support for the
hypothesis that fungi may be a risk factor in sarcoidosis is
found in two recent case-control studies cited earlier.5,6
Evidence that fungi may cause inflammation in the lungs is
found in a study on 11 patients with late-onset asthma and a
positive skin prick test to species of Trichophyton.8 They
were given Fluconazole for 5 months and there was a
significant decrease in airway reactivity to the fungal
antigen and an improvement of the symptoms of asthma.
The low antibody titre in serum and the absence of fungi
in the biopsies suggest that there was no fungal infectionwith active growth in the patients. If the causative agent in
the sarcoidosis patients that improved after antifungal
treatment were the presence of fungi in the lung or other
organs, the disease mechanism could be a late hypersensi-
tivity reaction, mediated by denditric cells and T-cell
lymphocytes.9,10 The fungal cell wall component (1-3)-b-
D-glucan could be important for such reactions.11,12 This
agent affects lymphocytes and macrophage function and
causes granulomas in the lungs.13 Some data suggest that it
induces a Th2-like response14,15 which could explain why
antibodies to a variety of different micro-organisms are
increased in patients with sarcoidosis.3
Molds and (1-3)-b-D-glucan have also been implied in the
pathogenesis of another granulomatous lung disease—hy-
persensitivity pneumonitis (HP). Sarcoidosis and HP share
some pathological characteristics and both diseases are less
common among smokers.16 In this material, none of the
cases were smokers as compared to a 35% prevalence of
smoking in the Slovenian population. HP is also accompanied
by general symptoms such as fatigue and weight loss, similar
to the condition often present among patients with
sarcoidosis.17
In conclusion, the results from this pilot, clinical inter-
vention study suggest that treatment with antifungal drugs
could comprise a useful addition to the conventional
treatment with corticosteroids in certain cases of sarcoi-
dosis. Further intervention studies are required to assess the
general validity of this conclusion.Acknowledgement
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